Newly diagnosed non-small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis

被引:5
|
作者
Zhu, Min [1 ]
Yi, Jiawen [1 ]
Su, Yanping [1 ]
Zhang, Yixiao [1 ]
Gao, Yanli [2 ]
Xu, Xiaoli [2 ]
Zhang, Shu [1 ]
Zhang, Yuhui [1 ]
Huang, Kewu [1 ]
机构
[1] Capital Med Univ, Beijing Chao Yang Hosp, Beijing Inst Resp Med, Dept Pulm & Crit Care Med, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Chao Yang Hosp, Dept Radiol, Beijing, Peoples R China
关键词
EGFR; interstitial lung abnormality; non-small cell lung cancer; usual interstitial pneumonia; ASSOCIATION; MUTATIONS; DISEASE; SMOKERS;
D O I
10.1111/1759-7714.14935
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Along with the improvement of lung cancer screening implementation, the identification of interstitial lung abnormality (ILA) is increasing. Currently, there is a limited description of the oncogenic status and ILA subtypes among newly diagnosed non-small cell lung cancer (NSCLC) patients with ILA in the Chinese population. This study aimed to investigate the prevalence, characteristics, oncogenic status and factors associated with overall survival (OS) among NSCLC patients with ILA.Methods: A total of 765 newly diagnosed NSCLC cases at our hospital were reviewed and ILA was diagnosed according to the criteria of the Fleischner Society. The characteristics, clinical pathological features and OS of NSCLC patients with ILA were retrospectively analyzed.Results: Of the 765 patients included in the study, 101 (13.2%) cases experienced ILA at the time of NSCLC diagnosis. Multivariate analysis revealed that ILA was more likely to be detected in NSCLC patients who were age =60 (OR 2.404, p = 0.001), male gender (OR 2.476, p = 0.004), and EGFR wild-type (OR 2.035, p = 0.007). Additionally, according to the multivariate Cox model, the presence of ILA in NSCLC patients was significantly associated with a shorter OS period than those without ILA (751 days vs. 445 days, HR 0.6, p = 0.001). Following analysis, it was determined that OS in patients with usual interstitial pneumonia (UIP) was shorter than in those without UIP (HR 1.82, p = 0.037).Conclusion: ILA is a common comorbidity among newly diagnosed NSCLC patients. We found that patients with EGFR wild-type NSCLC were more likely to develop ILA. The presence of ILA, especially UIP, was significantly associated with poor NSCLC prognosis.
引用
收藏
页码:1874 / 1882
页数:9
相关论文
共 50 条
  • [21] Fatal interstitial lung disease after erlotinib for non-small cell lung cancer
    Lind, Joline S. W.
    Smit, Egbert F.
    Grunberg, Katrien
    Senan, Suresh
    Lagerwaard, Frank. J.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (09) : 1050 - 1053
  • [22] Atezolizumab and nintedanib in patients with non-small cell lung cancer and interstitial lung disease
    Yamaguchi, Teppei
    Shimizu, Junichi
    Shigematsu, Fumie
    Watanabe, Naohiro
    Hasegawa, Takaaki
    Horio, Yoshitsugu
    Inaba, Yoshitaka
    Fujiwara, Yutaka
    JOURNAL OF THORACIC DISEASE, 2024, 16 (05) : 3371 - 3380
  • [23] Clinical Impact of Interstitial Lung Disease on Advanced Non-Small Cell Lung Cancer
    Oi, H.
    Taniguchi, H.
    Kondoh, Y.
    Kimura, T.
    Kataoka, K.
    Matsuda, T.
    Yokoyama, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2082 - S2082
  • [24] Characteristics and prognosis of resected T3 non-small cell lung cancer
    Riquet, M
    Lang-Lazdunski, L
    Le Pimpec-Barthes, F
    Dujon, A
    Souilamas, R
    Danel, C
    Manac'h, D
    ANNALS OF THORACIC SURGERY, 2002, 73 (01): : 253 - 258
  • [25] Radiation therapy in patients with non-small cell lung cancer and interstitial lung abnormalities
    Ito, M.
    Katano, T.
    Okada, H.
    Sakuragi, A.
    Minami, Y.
    Abe, S.
    Adachi, S.
    Oshima, Y.
    Kubo, A.
    Fukui, T.
    Ito, S.
    Suzuki, K.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1073 - S1074
  • [26] Impact of Interstitial Lung Disease on Survival for Patients with Non-small Cell Lung Cancer
    Miyazaki, Kunihiko
    Satoh, Hiroaki
    Kurishima, Koichi
    Nakamura, Ryota
    Ishikawa, Hiroichi
    Kagohashi, Katsunori
    Ohara, Gen
    Hizawa, Nobuyuki
    ANTICANCER RESEARCH, 2009, 29 (07) : 2671 - 2674
  • [27] Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
    Kato M.
    Shukuya T.
    Takahashi F.
    Mori K.
    Suina K.
    Asao T.
    Kanemaru R.
    Honma Y.
    Muraki K.
    Sugano K.
    Shibayama R.
    Koyama R.
    Shimada N.
    Takahashi K.
    BMC Cancer, 14 (1)
  • [28] Automated CT quantification of interstitial lung abnormality in patients with resectable stage I non-small cell lung cancer: Prognostic significance
    Chung, Jae Ho
    Park, Jong Myung
    Kim, Do Hyung
    THORACIC CANCER, 2024, 15 (16) : 1305 - 1311
  • [29] Diagnostic Yield of Staging Brain MRI in Patients with Newly Diagnosed Non-Small Cell Lung Cancer
    Kim, Minjae
    Suh, Chong Hyun
    Lee, Sang Min
    Kim, Ho Cheol
    Aizer, Ayal A.
    Yanagihara, Ted K.
    Bai, Harrison X.
    Guenette, Jeffrey P.
    Huang, Raymond Y.
    Kim, Ho Sung
    RADIOLOGY, 2020, 297 (02) : 419 - 427
  • [30] Preserved muscle oxidative metabolic phenotype in newly diagnosed non-small cell lung cancer patients
    Gosker, Harry
    den Kamp, Celine Op
    Kelders, Marco
    Dingemans, Annemarie
    Langen, Ramon
    Schols, Annemie
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46